Nurix Therapeutics, Inc. · NASDAQ:NRIX
Nurix Therapeutics — Technical Presentation (December 2020)
10 slides from Nurix Therapeutics's technical presentation, Dec 7, 2020
Slide 1: NX-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies
NX-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies Presenter: Daniel Robbins, Ph. D. drobbins@nurixtx.com Exhibit 99.1
Slide 2: Disclosures
Disclosures All authors of this presentation are current or former employees and shareholders of Nurix Therapeutics. ©Nurix Therapeutics. All rights reserved.
Slide 3: NX-2127 has a dual degradation mechanism of action for two clinically validated targets
NX-2127 has a dual degradation mechanism of action for two clinically validated targets ©Nurix Therapeutics. All rights reserved. BTK is a tyrosine kinase involved in B cell development, differentiation and signaling BTK inhibitors are approved for treatment of B cell malignancies Mutations to BTK h
Slide 4: NX-2127 catalyzes BTK degradation and anti-proliferative activity in cancer cell lines
NX-2127 catalyzes BTK degradation and anti-proliferative activity in cancer cell lines ©Nurix Therapeutics. All rights reserved. NX-2127 catalyzes potent degradation of BTK in DLBCL cell lines (TMD8), including cells with the ibrutinib-resistance mutation BTKC481S NX-2127 catalyzes BTK degradation i
Slide 5: NX-2127 has minimal in vitro effects on platelet aggregation
NX-2127 has minimal in vitro effects on platelet aggregation ©Nurix Therapeutics. All rights reserved. NX-2127 does not show significant inhibition of platelet aggregation in an in vitro platelet aggregation assay
Slide 6: NX-2127 catalyzes Aiolos degradation and IL-2 production similar to IMiD drugs
NX-2127 catalyzes Aiolos degradation and IL-2 production similar to IMiD drugs ©Nurix Therapeutics. All rights reserved. IMiD Activity: T Cell Activation and IL-2 Secretion IMiD Activity: Aiolos Degradation in Naïve Human T Cells NX-2127 degrades Aiolos with similar potency to that of pomalidomide a
Slide 7: Oral Administration of NX-2127 Demonstrates Cancer Growth Inhibition in Mouse Xenograft Tumor Model
Oral Administration of NX-2127 Demonstrates Cancer Growth Inhibition in Mouse Xenograft Tumor Model ©Nurix Therapeutics. All rights reserved. Tumor Growth Inhibition in Xenograft Model of Wild Type Lymphoma Tumor Growth Inhibition in Xenograft Model of Mutant Ibrutinib-Resistant Lymphoma NX-2127 dem
Slide 8: Oral Dosing of NX-2127 Degrades BTK in Cynomolgus Monkey
Oral Dosing of NX-2127 Degrades BTK in Cynomolgus Monkey ©Nurix Therapeutics. All rights reserved. BTK Levels in B cells at Day 19 BTK Levels in B cells at Day 1 NX-2127 induces significant degradation of BTK in 4 hours and more than 90% degradation through 24 hours post dose Once daily, oral dosing
Slide 9: Summary and Conclusions
Summary and Conclusions NX-2127 catalyzes potent BTK degradation in vitro and results in anti-proliferative effects in human lymphoma cell lines The IMiD activity of NX-2127 is similar to that of IMiD drugs pomalidomide and lenalidomide and results in T-cell activation NX-2127 demonstrates potent BT
Slide 10: Acknowledgements
Acknowledgements Chemistry Daisuke Kato Zef Konst Jose Leighton Oliver McConnell Joel McIntosh Ge Peng Josh Taygerly Jeffrey Wu Jeff Mihalic Christoph Zapf Development Timothy Ingallinera Janine Powers Jenny McKinnell Dane Karr Drug Discovery Technologies Eileen Ambing Andrew Sawayama Naimee Mehta H
Nurix Therapeutics — Technical Presentation (December 2020) on 6ix